Brief: Avenue Therapeutics Says First Patient Dosed In Phase 1B/2A Trial Of AJ201
27/07/2023 15:06
July 27 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1B/2A
CLINICAL TRIAL OF AJ201 FOR THE TREATMENT OF SPINAL AND BULBAR
MUSCULAR ATROPHY (KENNEDY'S DISEASE)
* AVENUE THERAPEUTICS INC - ENROLLMENT IN TRIAL IS EXPECTED
TO BE
COMPLETE BY END OF 2023 OR EARLY 2024 WITH POTENTIAL TOPLINE
DATA IN 2024
Source text for Eikon: ID:nGNX7yycjT
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary